Telisotuzumab-EMRELIS price and patient purchase reference information

Telisotuzumab (trade name EMRELIS) is a monoclonal antibody drug targeting c-Met . It is mainly used to treat patients with non-small cell lung cancer (NSCLC) with high expression of c-Met . The drug specifically binds to the c-Met protein, inhibits downstream signaling pathways, and prevents tumor cell proliferation and metastasis. It is a new drug option in the field of targeted therapy.

At present, terituzumab has not yet been launched in China, so domestic patients are temporarily unable to obtain the drug through formal channels. Due to the lack of domestic supply, patients who need to use the drug can only purchase the drug overseas. However, this involves many issues such as legal, logistics and medical supervision. Professional doctors and relevant institutions must be fully consulted before use.

In overseas markets, EMRELIS has been launched, with a price of approximately RMB 45,000 per box. There is currently no related generic version of this drug, so the price is relatively high. Overseas purchases need to be made through formal medical institutions or drug import channels to ensure drug quality and safety, and a doctor's prescription and detailed treatment plan are required.

In terms of drug purchase and use, patients should rationally plan treatment plans based on their own financial conditions and condition. Although it is currently not directly available in China, you can pay attention to clinical trials and international registration information, and you may obtain treatment opportunities through trials or special drug use. At the same time, while waiting for the official launch, the disease should be maintained stable through existing standard treatments to ensure patient safety and controllable efficacy.

Reference materials:https://www.drugs.com/